Q-omics provides the consensus-scored IL22 profile across patient tissues and cancer cell-line models. IL22 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, IL22 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, IL22 protein abundance shows 20,530 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, HNSC, and LUAD as cancer lineages where IL22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL22 survival associations across molecular data types. IL22 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL22 RNA expression–survival associations across cancer types. High IL22 expression shows unfavorable associations in KIRC, STAD, LUSC and DLBC, but favorable associations in BLCA and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for IL22 RNA expression.
This table summarizes IL22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL22 shows lower tumor expression in HNSC and THCA and higher tumor expression in KIRC. The HNSC box plot shows higher IL22 RNA expression in normal versus tumor tissue (log2 FC = −0.838, t-test p < 0.001).
This table shows molecular features associated with IL22 in patient tissues and cancer cell lines. In patient samples, IL22 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IL22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
